Evelo Biosciences Says Co. & Abdul Latif Jameel Health Entered Strategic Collaboration
Reuters reports that Evelo Biosciences and Abdul Latif Jameel Health have entered a strategic collaboration to develop and commercialize Evelo’s novel therapy EDP1815 for inflammatory diseases and COVID-19 in select developing markets serving 1.7 billion people.
Read the full article in its original location here.
For press inquiries click here, or call +971 4 448 0906 (GMT +4 hours UAE). For public inquiries click here.